Table 2 |
|||||
|
Intradermal skin test results using B. bassiana extract |
|||||
|
Patient ID |
Histamine control1 (0.1 mg/ml) |
B. bassiana Extract (1 mg/ml) |
B. bassiana/Histamine |
||
|
|
|||||
|
Induration2 |
Erythema2 |
Induration2 |
Erythema2 |
Induration ratio3 |
|
|
|
|||||
|
J4,5 |
7 × 6 |
12 × 16 |
8 × 8 |
12 × 13 |
0.65 |
|
K4,5 |
20 × 15 |
55 × 50 |
13 × 12 |
14 × 13 |
0.52 |
|
L4,5 |
11 × 10 |
16 × 33 |
13 × 14 |
26 × 28 |
1.65 |
|
M4,5 |
15 × 16 |
36 × 44 |
10 × 12 |
10 × 12 |
0.30 |
|
N |
16 × 14 |
38 × 58 |
10 × 11 |
21 × 17 |
0.49 |
|
O |
21 × 16 |
39 × 59 |
9 × 8 |
18 × 21 |
0.21 |
|
P |
15 × 17 |
44 × 45 |
5 × 4 |
5 × 4 |
0.08 |
|
Q |
15 × 14 |
36 × 38 |
9 × 12 |
10 × 13 |
0.51 |
|
R |
15 × 15 |
55 × 38 |
4 × 4 |
11 × 13 |
0.07 |
|
S4 |
20 × 19 |
38 × 43 |
4 × 4 |
4 × 4 |
0.04 |
|
|
|||||
|
1In all instances saline control injections produced indurations of 3–4 mm × 3–4 mm. 2Values recorded in mm × mm. 3Induration ratio expressed as B. bassiana reaction area (mm2)/histamine reaction area (mm2). 4Individual with occupational exposure to Beauveria bassiana. 5See Western Blot results for individual, Fig. 2. |
|||||
|
Westwood et al. Clinical and Molecular Allergy 2005 3:1 doi:10.1186/1476-7961-3-1 |
|||||